Bolt Biotherapeutics (Nasdaq:BOLT) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

BOLT Overzicht aandelen

Bolt Biotherapeutics, Inc., een biofarmaceutisch bedrijf in een klinische fase, houdt zich bezig met de ontwikkeling van immuuntherapieën voor de behandeling van kanker.

Over het bedrijf

BOLT fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 16.4% per jaar groeien

Risicoanalyse

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft geen betekenisvolle marktkapitalisatie ( $25M )

Bolt Biotherapeutics, Inc. Concurrenten

CytoMed Therapeutics

NasdaqCM:GDTC

US$18.9m

Lumos Pharma

NasdaqGM:LUMO

US$29.2m

Marker Therapeutics

NasdaqCM:MRKR

US$24.2m

Palatin Technologies

NYSEAM:PTN

US$17.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Bolt Biotherapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$0.65
52 Week Hoogtepunt	US$1.56
52 Week Laag	US$0.55
Bèta	0.93
11 maand verandering	-4.63%
3 maanden verandering	-12.38%
1 Jaar Verandering	-33.39%
33 jaar verandering	-94.97%
5 jaar verandering	n/a
Verandering sinds IPO	-97.99%

Recent nieuws en updates

Recent updates

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

May 21

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Mar 15

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

May 13

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Dec 01

Bolt Biotherapeutics: A Promised Follow Up

Aug 26

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

Aug 10

Rendement voor aandeelhouders

	BOLT	US Biotechs	US Markt
7D	10.2%	-0.2%	-0.4%
1Y	-33.4%	22.1%	34.1%

Rendement versus industrie: BOLT presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 22.1 % opleverde.

Rendement versus markt: BOLT presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 34.1 % opleverde.

Prijsvolatiliteit

Is BOLT's price volatile compared to industry and market?
BOLT volatility
BOLT Average Weekly Movement	4.5%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: BOLT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van BOLT is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	100	Willie Quinn	www.boltbio.com

Bolt Biotherapeutics, Inc, een biofarmaceutisch bedrijf in een klinische fase, houdt zich bezig met de ontwikkeling van immuuntherapieën voor de behandeling van kanker. De belangrijkste productkandidaat van het bedrijf, BDC-1001, is in klinische ontwikkeling voor de behandeling van patiënten met humane epidermale groeifactorreceptor 2-positieve vaste tumoren, waaronder borst-, colorectale, endometriale en gastro-oesofageale kanker. Het ontwikkelt ook BDC-3042, een agonistisch antilichaam gericht tegen Dectin-2 voor een reeks tumoren, zoals hoofd- en nekkanker, niet-kleincellige longkanker, eierstokkanker, triple-negatieve borstkanker en andere kanker.

Bolt Biotherapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Bolt Biotherapeutics zich tot de beurswaarde?
BOLT fundamentele statistieken
Marktkapitalisatie	US$24.80m
Inkomsten(TTM)	-US$66.17m
Inkomsten(TTM)	US$11.17m

2.2x

P/S-verhouding

-0.4x

Koers/Winstverhouding

Is BOLT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BOLT resultatenrekening (TTM)
Inkomsten	US$11.17m
Kosten van inkomsten	US$63.24m
Brutowinst	-US$52.07m
Overige uitgaven	US$14.10m
Inkomsten	-US$66.17m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.73
Brutomarge	-466.32%
Nettowinstmarge	-592.57%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde BOLT op de lange termijn?

Bekijk historische prestaties en vergelijking

BOLT Overzicht aandelen

Beloningen

Risicoanalyse

Bolt Biotherapeutics, Inc. Concurrenten

NasdaqCM:GDTC

US$18.9m

NasdaqGM:LUMO

US$29.2m

NasdaqCM:MRKR

US$24.2m

NYSEAM:PTN

US$17.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

High number of new directors

Bolt Biotherapeutics, Inc. Announces Changes to Its Board of Directors

Consensus EPS estimates fall by 13%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Recent updates

High number of new directors

Bolt Biotherapeutics, Inc. Announces Changes to Its Board of Directors

Consensus EPS estimates fall by 13%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Pomerantz Law Firm Announces the Filing of A Class Action Against Bolt Biotherapeutics, Inc. and Certain Officers - BOLT

High number of new directors

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

Consensus revenue estimates decrease by 12%, EPS upgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bolt Biotherapeutics, Inc., Annual General Meeting, Jun 12, 2024

Consensus revenue estimates increase by 44%, EPS downgraded

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Price target increased by 9.4% to US$5.25

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu

Consensus revenue estimates increase by 21%

Bolt Biotherapeutics, Inc. Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Price target decreased by 7.7% to US$4.80

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Bolt Biotherapeutics, Inc. Appoints Laura Berner to Board of Directors

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$6.40

Bolt Biotherapeutics: A Promised Follow Up

Consensus revenue estimates increase by 36%

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Bolt Biotherapeutics, Inc.(NasdaqGS:BOLT) dropped from Russell 2500 Index

Price target decreased to US$11.50

High number of new directors

We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Bolt Biotherapeutics, Inc. Announces Resignation of David Dornan as Chief Scientific Officer, Effective from March 11, 2022

Price target decreased to US$13.67

Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors

Less than half of directors are independent

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth

Consensus revenue estimates fall to US$1.00m

Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies

We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely

Bolt Biotherapeutics, Inc.(NasdaqGS:BOLT) dropped from Russell 3000E Growth Index

Bolt Biotherapeutics, Inc. announced that it has received $15 million in funding from Genmab A/S

Bolt Biotherapeutics, Inc. Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021

Bolt Biotherapeutics, Inc. announced that it expects to receive $15 million in funding from Genmab A/S

Full year 2020 earnings released: US$28.89 loss per share (vs US$15.29 loss in FY 2019)

Bolt Biotherapeutics, Inc. has completed an IPO in the amount of $230 million.

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Bolt Biotherapeutics, Inc. Samenvatting

2.2x

-0.4x

Inkomsten en omzet